Efficacy of empagliflozine in experimental chronic heart failure in normoglycemia

• Alexander N. Kulikov
• Marina V. Krasnova
• Dmitriy Yu. Ivkin
• Andrey A. Karpov
• Elena Kaschina
• Sergey V. Okovityy
• Nataliya V. Demakova

Abstract

A comparative experimental study of the empagliflozin efficacy of (intragastric 1 mg/kg) in monotherapy in the treatment of experimental chronic heart failure (CHF) in normoglycemia was conducted. Pathology was modeled by permanent ligation of the left coronary artery. One month after surgery under control echocardiographic (Echo), the animals were randomized to five groups depending on the amount of basic CHF therapy (sodium-glucose co-transporter type 2 inhibitor, angiotensin-converting-enzyme inhibitors (ACE inhibitors), β-blockers, aldosterone antagonist) or placebo.

Three months from the start of the treatment, the analysis of Echo and physical tolerance was repeated. Treatment with an inhibitor sodium-glucose cotransporter type 2 (iSGLT2) empagliflozin has been found to prevent the death of animals from CHF. By slowing down the development of impaired left ventricular activity, the drug is inferior only to ACE inhibitors, and by diuretic effect to the aldosterone antagonist. In addition, its use allows to achieve maximum tolerance to exercise in comparison with other used drugs.

Keywords:chronic heart failure, sodium-glucose co-transporter type 2 inhibitors, empagliflozin

References

1. Zinman B., Wanner C., Lachin J.M., et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373 (22): 2117-28.

2. Kulikov A.N., Okovitiy S.V., Ivkin D. Yu. et al. Effects of empagliflozin in an experimental model of chronic heart failure in normoglycemic rats. Serdechnaya nedostatochnost’ [Heart Failure]. 2016; (6): 454-60. (in Russian)

3. Anker S.D., Butler J., Filippatos G., et al. Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial. Circulation. 2021; 143 (4): 337-49.

4. Anker S.D., Butler J., Filippatos G., et al.; EMPEROR-Preserved Trial Committees and Investigators. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. 2019; 21 (10): 1279-87.

5. McMurray J.J.V., Solomon S.D., Inzucchi S.E., et al.; DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019; 381 (21): 1995-2008.

6. Karpov A.A., Ivkin D. Yu., Dracheva A.V., et al. Rat model of postinfarct heart failure by left coronary artery occlusion: technical aspects, functional and morphological assessment. Biomeditsina [Biomedicine]. 2014; 1 (3): 32-48. (in Russian)

7. Kazachenko А.А., Okovitiy S.V., Kulikov A.N., et al. Comparative characteristics of some pharmacological models of chronic heart failure. Eksperimental’naya i klinicheskaya farmakologiya [Experimental and Clinical Pharmacology]. 2008; 71 (6): 16-9. (in Russian)

8. Butler J., Usman M.S., Khan M.S., et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020; 7 (6): 3298-309.

9. Martens P., Janssens J., Ramaekers J., et al. Contemporary choice of glucose lowering agents in heart failure patients with type 2 diabetes. Acta Cardiol. 2020; 75 (3): 211-7.

10. Watanabe K., Ohta Y., Inoue M., et al. Bisoprolol improves survival in rats with heart failure. J Cardiovasc Pharmacol. 2001; 38 (suppl 1): 55-8.

11. Nishio M., Sakata Y., Mano T., et al. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail. 2008; 10 (5): 446-53.

12. Santos-Gallego C.G., Requena-Ibanez J.A., San Antonio R., et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. JACC Cardiovasc Imaging. 2021; 14 (2): 393-407.

13. Uthman L., Baartscheer A., Bleijlevens B., et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na⁺/H⁺ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018; 61 (3): 722-6.

14. Thapa S.S., Lal A., Omer A., Trivedi N. Elevated p-hydroxybutyric acid with no ketoacidosis in type 2 diabetic patients using sodium-glucose cotransporter-2 inhibitors. J Formos Med Assoc. 2019; 118 (10): 1473-4.

15. Chung Y.J., Park K.C., Tokar S., et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na⁺/H⁺ exchanger-1 or lower [Na+]i in the heart. Cardiovasc Res. 2020; 2020: cvaa323.

16. Cappetta D., de Angelis A., Ciuffreda L.P., et al. Amelioration of diastolic dysfunction by dapagliflozin in a non-diabetic model involves coronary endothelium. Pharmacol Res. 2020; 157: 104781.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)